COVID-19 pandemic affecting valuations of some ophthalmic companies

The COVID-19 pandemic may change the way industry leaders in health care markets invest in or acquire smaller to mid-sized companies, as the slowdown in the economy has forced down companies’ valuations, a speaker said during an Eyecelerator LiveStream presentation.
In the first of a series of events hosted by Eyecelerator, four ophthalmic industry leaders discussed their views of and strategies for investing in ophthalmic companies during the global pandemic. David Endicott, Alcon CEO; Warren Foust, Johnson & Johnson Vision worldwide president, surgical division; Jim Mazzo, Zeiss

Full Story →